Research-Studie


Original-Research: Aspermont Limited - von GBC AG

Einstufung von GBC AG zu Aspermont Limited

Unternehmen: Aspermont Limited
ISIN: AU000000ASP3

Anlass der Studie: Research Update
Empfehlung: BUY
Kursziel: 0,09 AUD
Kursziel auf Sicht von: 31.12.2022
Letzte Ratingänderung:
Analyst: Julien Desrosiers; Felix Haugg

Impressive revenue growth and notable raise in gross profit

Aspermont's performance demonstrates the company's ability to grow at a
fast rate. When compared to Q4-2020, the company's revenues increased in
all sectors in Q4-2021. Currently, we can only look at partial numbers due
to Australian stock market regulatory laws.

These figures show a clear increase in all revenue sectors. Their XaaS and
service sectors grew by 20% and 17%, respectively, and now account for over
85% of total revenue. Their new data sector grew at a rate of 162%. Because
this division is less developed, faster growth is expected. Nonetheless, it
demonstrates how much potential management saw in this opportunity.

The increase in revenue did not result in a proportional increase in gross
profits margin. The quarter-on-quarter increase was only 12%, half of the
total revenue increase of 24%. This is unsurprising, as we believe
Aspermont needed to invest more money to maintain its current level of
growth and develop the new Data sector, as evidenced by their Q4-2021 OPEX
increase. Direct OPEX costs increased by 33%, owing to investments in new
businesses and increased operational capacity to support long-term growth.
All new investments are adequately funded by internal cash flow.

However, reaching a gross margin of 65% is a significant achievement. We
believe that the key to their new development strategy was to generate
higher margins and use the extra cash flow to fuel growth. This appears to
be working for the company at the moment, and we are eagerly awaiting the
full Q4-2021 and FY-2021 results, which should be released very soon, to
confirm our position.

In the fourth quarter, Aspermont experienced two significant events. The
company announced the establishment of a new fintech joint venture as well
as the launch of their first-generation capital raising platform.
Aspermont's current product offering in the mining sector will be enhanced
by the new partnership with Spark Plus and IPC. Spark Plus is a corporate
advisory firm that specializes in Asian roadshows for Asian companies. IPC
is a Sydney-based licensed securities dealer. Across Asia and Australia,
they provide Wealth Management and Corporate Advisory services to wholesale
and sophisticated investors.

The importance of the capital raising sector cannot be overstated. This is
a fiercely competitive industry that is undergoing a complete
transformation. Traditional banks and institutions continue to dominate the
market, but new entrants are gaining traction.
We believe that Aspermont unique position in the mining sector can pave the
way for important financing activities and the timing of the company could
not be better as the commodities have now entered in a super cycle. The
association with both Spark Plus, and IPC could generate substantial cash
flow within the next few years.

We believe the gross profits to be very healthy and the growth to be in
line with our expectations. We therefore confirm our buy rating with a 0.09
AUD target price.

Die vollständige Analyse können Sie hier downloaden:
http://www.more-ir.de/d/23119.pdf

Kontakt für Rückfragen
GBC AG
Halderstraße 27
86150 Augsburg
0821 / 241133 0
research@gbc-ag.de
+++++++++++++++
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter:
http://www.gbc-ag.de/de/Offenlegung
+++++++++++++++
Date and time of completion of this research: 19.11.2021 (05:58 pm)
Date and time of first distribution: 19.11.2021 (08:00 am)

-------------------übermittelt durch die EQS Group AG.-------------------


Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw.
Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung
oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021